MedPath

Intrauterine Hyaluronic Acid Gel for Prevention of Intrauterine Adhesions

Not Applicable
Conditions
Prevenetion of Intrauterine Adhesions by Hyaluronic Acid Gel
Interventions
Drug: Intrauterine injection of hyaluronic acid
Registration Number
NCT04975373
Lead Sponsor
Barzilai Medical Center
Brief Summary

Women undergoing operative hysteroscopy for removal of retained placenta after delivery will be randomized into two groups.

1. study group - immediately after operative hysteroscopy 5 ml hyaluronic acid gel will be injected into uterine cavity

2. control group - no injection

4-8 weeks after operative hysteroscopy, participants will undergo diagnostic hysteroscopy with no anesthesia , as a part of routine evaluation after removal of retained placenta in Israel.

during diagnostic hysteroscopy the uterine cavity will be evaluated and the presence of adhesions and severity of adhesions will be recorded.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
160
Inclusion Criteria
  • Women undergoing hysteroscopic removal of retained placenta after delivery
Exclusion Criteria
  • Known adverse reaction or allergy to hyaluronic acid

History of intrauterine adhesions

Acute pelvic inflammatory disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
study groupIntrauterine injection of hyaluronic acidstudy group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
Primary Outcome Measures
NameTimeMethod
any adhesions4-8 weeks after intervention

presence of any adhesions in uterine cavity during diagnostic hysteroscopy

Secondary Outcome Measures
NameTimeMethod
adhesion scorring4-8 weeks after intervention

American Fertility Society score for intrauterine adhesions

Trial Locations

Locations (1)

Barzilai University Medical Center

🇮🇱

Ashkelon, Israel

© Copyright 2025. All Rights Reserved by MedPath